Hutchmed China (HCM.US) Financial Statements - Balance Sheet/Income Statement/Cash Flow - Longbridge

Quote List Quote List

Event Tracking

Dec30

Hopewell Healthcare's Savolitinib New Drug Application Accepted by China's National Drug Regulatory Authority

10:20

Chi-Med's MET inhibitor savolitinib NDA accepted and granted priority review by NMPA

10:00

Dec29

Chi-Med's Fanregratinib Receives NMPA Priority Review

08:31

Dec17

Hopewell 启动 HMPL-A251 的全球 I 期临床试验

00:00

Dec8

HUTCHMED Pharmaceuticals' Medicines Renewed for National Health Insurance and Innovative Commercial Health Insurance Drug Catalog

00:16

Nov28

Hutchmed China Ltd Announces Issued Share Capital as of November 28, 2025

08:31

Schedules & Filings

Schedules

Filings

Aug7

Earning Release(EST)

FY2025 Q2 Earning Release (USD) Revenue 138.84 M, Net Income 227.48 M, EPS 1.3

Mar19

Earning Release(EST)

FY2024 Q4 Earning Release (USD) Revenue 162.26 M, Net Income 5.964 M, EPS 0.025

Jul31

Earning Release(EST)

FY2024 Q2 Earning Release (USD) Revenue 152.84 M, Net Income 12.9 M, EPS 0.075

View More

Stock List

Top Gainers

Top Decliners

China Concepts

Symbol

Price

%Chg

Change

View More